Mount Vernon Clinical Research, LLC   Report issue

For profit Phase 2 Phase 3
Founded: Atlanta GA United States (2004)

Organization Overview

First Clinical Trial
2006
NCT00285207
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2010

Timeline

NOW
  • Now

Alternative names

Mount Vernon Clinical Research, LLC, Sandy Springs, GA 30328

Active Ingredients

Drugs in Phase 3 Trials (1)

paroxetine (paxil) (1 trial)

Drugs in Phase 2 Trials (1)

sivifene (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cervical Intraepithelial Neoplasia (Phase 2)

Hot Flashes (Phase 3)

Neoplasms (Phase 2)

Squamous Intraepithelial Lesions of the Cervix (Phase 2)

Uterine Cervical Dysplasia (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2